Kyle L. Hoehn received his BA in Chemistry and Biology from the University of Northern Colorado in 2000, and he completed his MS and Ph.D. in Biochemistry from Colorado State University in 2001 and 2005, respectively. He is now a Professor at the School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney. His lab develops novel mitochondrial uncoupler drugs for the treatment of metabolic disorders, including obesity, aging, and diabetes. His research projects include developing new molecules that improve healthy aging, developing molecules that reverse obesity and related metabolic disorders, and understanding the role of acetyl-CoA carboxylase enzymes in nutrient metabolism.